Egészségügyi Közgazdaságtan Tanszék
Budapesti Corvinus Egyetem

Idegen nyelvű közlemények

2017.

Brodszky V, Bíró A, Szekanecz Z, Soós B, Baji P, Rencz F, Tóthfalusi L, Gulácsi L, Péntek M, Determinants of drug survival of biological therapies in rheumatoid arthritis:evidence from a Hungarian rheumatology center over 8 years or retrospective data, Clinico Economics and Outcomes Research, 2017:9 139–147. https://www.dovepress.com/articles.php?article_id=31340Link to the paper on PubMed:http://www.ncbi.nlm.nih.gov/pubmed/28243133 IF: – ;Scimago: Q1.

Petra Baji, László Gulácsi, Csaba Horváth, Valentin Brodszky, Fanni Rencz, MártaPéntek, Comparing self-perceived and estimated fracture risk by FRAX® of women with osteoporosis, Arch Osteopporos. 2017,12(1):4. DOI 10.1007/s11657-016-0300-5 IF (2016):1.960; Scimago: Q2.

Laszlo Gulacsi, Marta Pentek, Fanni Rencz, Valentin Brodszky, Petra Baji, Zsuzsanna, Vegh, Krisztina B Gecse, Silvio Danese, Laurent Peyrin-Biroulet, Peter L. Lakatos, Biosimilars for the management of inflammatory bowel diseases: economic considerations, 2017, Current Medicinal Chemistry DOI 10.1007/s12325-017-0522-y IF (2016): 3.249; Scimago: Q2.

László Gulácsi, Valentin Brodszky, Petra Baji, Fanni Rencz, Márta Péntek, The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries, Adv Ther (Advances in Therapy), 2017, 34(5), 1128-1144. DOI 10.1007/s12325-017-0522-y, IF (2016): 2.709; Scimago: Q1. http://link.springer.com/article/10.1007/s12325-017-0522- y?wt_mc=Internal.Event.1.SEM.ArticleAuthorOnlineFirst

Petra Baji, László Gulácsi, Valentin Brodszky, Végh Zsuzsanna, Silvio Danese, Peter M. Irving, Laurent Peyrin Biroulet, Stefan Schreiber, Fanni Rencz, Cost-effectiveness of biological treatment sequences for fistulising Crohn’s disease across Europe, United European Gastroenterology Journal, 2017. DOI: 10.1177/2050640617708952 IF (2016): 3.673; Scimago: Q3.

Fanni Rencz, László Gulácsi, Márta Péntek, Krisztina B. Gecse, Axel Dignass, Jonas Halfvarson, Fernando Gomollón, Petra Baji, Laurent Peyrin-Biroulet, Péter L. Lakatos, Valentin Brodszky, Cost-utility of biological treatment sequences for luminal Crohn’s disease in Europe, Expert Review of Pharmacoeconomics & Outcomes Research, 17(6): 597- 606. DOI:10.1080/14737167.2017.1322509 IF: 1.631; Scimago: Q2.

Márta Péntek, Gisela Kobelt, Jenny Berg, Daniela Capsa, Johan Dalén, Zita Bíró, Klotild Mátyás, Sámuel Komoly and The European Multiple Sclerosis Platform, New insights into the burden and costs of multiple sclerosis in Europe: Results for Hungary, Multiple Sclerosis Journal 2017, Vol. 23(2S) 91–103, DOI: 10.1177/1352458517708142, IF (2016): 4.840; Scimago Q1.

Cecília Varjú, Márta Péntek, Veronika Lóránd, Gabriella Nagy, Tünde Minier, László Czirják. Musculoskeletal involvement in systemic sclerosis: an unexplored aspect of the 8 disease. JOURNAL OF SCLERODERMA AND RELATED DISORDERS 2:(1) pp. 19-32. (2017) IF: – ;Scimago: –

Zsombor Zrubka, Economic aspects of biosimilar competition in Hungary, The treatment of rheumatic disorders, Society and Economy 39 (2017) 2, pp. 271–290, DOI: 10.1556/204.2017.39.2.6 IF: – ; Scimago: Q3.

Baji P, Rubashkin N, Szebik I, Stoll K, Vedam S: Informal cash payments for birth in Hungary: Are women paying to secure a known provider, respect, or quality of care?. Social Science & Medicine 2017 Sep;189:86-95. IF (2016): 2.797; Scimago: Q1. (D1)

Fanni Rencz, Márta Péntek, Peep FM Stalmeier, Valentin Brodszky, Gábor Ruzsa, Edina Gradvohl, Petra Baji, László Gulácsi, Bleeding out the QALYs: evaluating the burden of primary dysmenorrhea by time trade-off and willingness-to-pay methods, Pain, 158(11): 2259-2267 doi: 10.1097/j.pain.0000000000001028; IF (2016): 5.445; Scimago: Q1 (D1).

Valentin Brodszky,Péter Varga, Judit Gimesi-Országh, Petra Fadgyas-Freyler, Imre Boncz, Péter Nyirády, Péter Riesz, Petra Baji, Márta Péntek, Fanni Rencz, László Gulácsi, Long-term costs and survival in prostate cancer; a population based study, International Urology and Nephrology (UROL), 2017 DOI 10.1007/s11255-017-1669-9, IF (2016): 1.292; Scimago: Q2.

Márta Péntek, Péter L Lakatos, Talitha Oorsprong, László Gulácsi, Milena Pavlova, Wim Groot, Fanni Rencz, Valentin Brodszky, Petra Baji and Crohn’s Disease Research Group, Access to biologicals in Crohn’s disease in ten European countries, World Journal of Gastroenterology. 2017, 23 volume 34 issue, 6294-6305. open access IF (2016): 3.365; Scimago Q1.

Fábián M, Rencz F, Krenács T, Brodszky V, Hársing J, Németh K, Sárdy M, Balogh P, Kárpáti S. (2017) Expression of G-protein coupled oestrogen receptor, GPER in melanoma and in pregnancy-associated melanoma. Journal of the European Academy of Dermatology and Venereology 2017 May 3. doi: 10.1111/jdv.14304. [Epub ahead of print] IF (2016) 3.528; Scimago Q1 (D1).

Zsombor Zrubka, Fanni Rencz, Jakub Závada, Dominik Golicki, Valentina Prevolnik Rupel, Judit Simon, Valentin Brodszky, Petra Baji, Guenka Petrova, Alexandru Rotar, László Gulácsi, Márta Péntek, EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic review of the literature review and meta-analysis, Rheumatology International, 37(12):1957-1977 doi: 10.1007/s00296-017-3800-8. IF (2016): 1.824; Scimago: Q2.

Adrienn Katalin Poór, Fanni Rencz, Valentin Brodszky, László Gulácsi, Zsuzsanna Beretzky, Bernadett Hidvégi, Péter Holló, Sarolta Kárpáti, Miklós Sárdy, Márta Péntek, Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients, Quality of Life Research (accepted) IF (2016): 2.344; Scimago Q1.

Márta Péntek, Valentin Brodszky, Zsolt Biró, Zsófia Kölkedy, Árpád Dunai, János Németh, Petra Baji, Fanni Rencz, Laszlo Gulacsi, Miklos D Resch, Subjective health expectations of patients with age-related macular degeneration treated with antiVEGF drugs, BMC Geriatrics 2017, 17:233, https://doi.org/10.1186/s12877-017-0619-9, https://bmcgeriatr.biomedcentral.com/articles, IF (2016): 2.611; Scimago Q1.

F Rencz, AK Poór, M Péntek, P Holló, S Kárpáti, L Gulácsi, A Szegedi, É Remenyik, B Hidvégi, K Herszényi, H Jókai, Z Beretzky, V Brodszky, A detailed analysis of ‘not relevant’ responses on the DLQI in psoriasis: potential biases in treatment decisions, Journal 9 of the European Academy of Dermatology & Venereology. 2017 Nov 8. doi: 10.1111/jdv.14676. IF (2016): 3.528; Scimago: Q1 (D1).

Hifinger M, Hiligsmann M, Ramiro S, Watson V, Severens JL, Fautrel B, Uhlig T, van Vollenhoven R, Jacques P, Detert J, Canas da Silva J, Scire CA, Berghea F, Carmona L, Pentek M, Keat A, Boonen A. Economic considerations and patients’ preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists. ANNALS OF THE RHEUMATIC DISEASES 76:(1) pp. 126- 132. (2017) IF (2016): 12.811; Scimago Q1 (D1).

Hifinger M, Hiligsmann M, Ramiro S, Watson V, Berghea F, Pentek M, Keat A, Severens JL, Fautrel B, Boonen A. Influence of disease activity on RA treatment choices in countries with restricted access to expensive, innovative drugs: a discrete choice experiment among rheumatologists. RMD OPEN 3:(2) p. e000453. (2017) IF: -; Scimago –

Kumánovics G, Péntek M, Bae S, Opris D, Khanna D, Furst DE, Czirják L. Assessment of skin involvement in systemic sclerosis.Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v53-v66. doi: 10.1093/rheumatology/kex202. IF (2016): 4.818; Scimago: Q1 (D1).

Adrienn Katalin Poór, Valentin Brodszky, Márta Péntek, László Gulácsi, Gábor Ruzsa, Bernadett Hidvégi, Péter Holló, Sarolta Kárpáti, Miklós Sárdy, Fanni Rencz, Is the Dermatology Life Quality Index appropriate for medical decision-making in psoriasis patients? Archives of Dermatological Research, 2017 accepted for publication IF (2016): 2,327, Scimago: Q1.

Rubashkin N, Szebik I, Baji P, Szántó Z, Susánszky É, Vedam S. Assessing quality of maternity care in Hungary: expert validation and testing of the mother-centered prenatal care (MCPC) survey instrument. Reprod Health. 2017 Nov 16;14(1):152. IF (2016): 2.209, Scimago Q1.

Pentek M, Zrubka Z, Gulacsi L. The economic impact of biosimilars on chronic immune-mediated inflammatory diseases. Curr Pharm Des. 2017 Nov 29. doi: 10.2174/1381612824666171129193708 IF (2016): 2,611 Scimago: Q1.

 

 

2016.


 

Rencz F, Brodszky V, Stalmeier P.F.M., Tamási B, Kárpáti S, Péntek M, Baji P, Mitev A.Z., Gulácsi L, Estimating utility values for pemphigus vulgaris and foliaceus by the general public: a composite time trade-off study, British Journal of Dermatology, 2016 (accepted) doi: 10.1111/bjd.14647. IF (2014) 4.275

László Gulácsi, Fanni Rencz, Gyula Poór, Zoltán Szekanecz, Valentin Brodszky, Petra Baji, Márta Péntek, Patients’ access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the inter-country differences, Annals of the Rheumatic Diseases the EULAR Journal, 2016 (accepted). 10.1136/annrheumdis-2015-208741. IF (2014): 10.377

Thomas Dörner, Vibeke Strand, Paul Cornes, João Gonçalves, László Gulácsi, Jonathan Kay, Tore K Kvien, Josef Smolen, Yoshiya Tanaka, Gerd R. Burmester, The changing landscape of biosimilars in rheumatology, Annals of the Rheumatic Diseases the EULAR Journal, 2016 (acceptd) doi: 10.1136/annrheumdis-2016-209166. IF (2014): 10.377

Fanni Rencz, Petra Baji, Márta Péntek, Norbert Wikonkál, László Gulácsi, Valentin Brodszky, Alopecia areata and health-related quality of life: a systematic review and meta-analysis, British Journal of Dermatology, 2016 (accepted) doi: 10.1111/bjd.14497, IF (2014): 4.275

Petra Baji, Efficacy and safety of biosimilar infliximab compared to other biologicals in rheumatoid arthritis, GaBi Online, 2016. http://www.gabionline.net/Biosimilars/Research/Efficacy-and-safety-of-biosimilar-infliximab-compared-to-other-biologicals-in-rheumatoid-arthritis

Baji P , Gulácsi L , Lovász BA , Golovics PA ,, Brodszky V , Péntek M , Rencz F, Lakatos PL, Treatment preferences of originator vs. biosimilar drugs in Crohn’s disease; discrete choice experiment among gastroenterologists, Scandinavian Journal of Gastroenterology 2016. 51:(1) pp. 22-27. IF (2014): 2.361

Péntek M , Gulácsi L , Tóth E , Baji P , Brodszky V,  Horvath C, A szakellátásban megjelenő osteoporosisos nők 10 éves csonttöréskockázata a FRAX® alapján, Orvosi Hetilap 2016. 157:(4) pp. 146-153. IF (2015, estimated): 0.26

Karine Chevreul, Morgane Michel, Karen Berg Brigham, Julio López-Bastida, Renata Linertová, Juan Oliva-Moreno, Pedro Serrano-Aguilar, Manuel Posada-de-la-Paz, Domenica Taruscio, Arrigo Schieppati, Georgi Iskrov, Márta Péntek, Johann Matthias Graf von der Schulenburg, Panos Kanavos, Ulf Persson, Giovani Fattore and BURQOL-RD Research Network, Social/Economic Costs and Health-Related Quality of Life in Patients with Cystic Fibrosis in Europe, European Journal of Health Economics, Supplement, 2016 10.1007/s10198-016-0781-6 (accepted) IF (2014): 1.774

Aris Angelis, Panos Kanavos, Julio López-Bastida, Renata Linertová, Juan Oliva-Moreno, Pedro Serrano-Aguilar, Manuel Posada-de-la-Paz, Domenica Taruscio, Arrigo Schieppati, Georgi Iskrov, Valentin Brodszky, Johann Matthias Graf von der Schulenburg, Karine Chevreul, Ulf Persson, Giovanni Fattore and BURQOL-RD Research Network, Social/Economic Costs and Health-Related Quality of Life in Patients with Epidermolysis Bullosa in Europe, European Journal of Health Economics, Supplement, 2016 10.1007/s10198-016-0783-4 (accepted) IF (2015): 1.774

Karine Chevreul, Coralie Gandré, Karen Berg Brigham, Julio López-Bastida, Renata Linertová, Juan Oliva-Moreno, Pedro Serrano-Aguilar, Manuel Posada-de-la-Paz, Domenica Taruscio, Arrigo Schieppati, Georgi Iskrov, László Gulácsi, Johann Matthias Graf von der Schulenburg, Panos Kanavos, Ulf Persson , Giovani Fattore and BURQOL-RD Research Network, Social/Economic Costs and Health-Related Quality of Life in Patients with Fragile X Syndrome in Europe, European Journal of Health Economics, Supplement, 2016 10.1007/s10198-016-0784-3 (accepted) IF (2014): 1.774

Marianna Cavazza, Yllka Kodra, Patrizio Armeni1, Marta De Santis, Julio López-Bastida, Renata Linertová, Juan Oliva-Moreno, Pedro Serrano-Aguilar, Manuel Posada-de-la-Paz, Domenica Taruscio, Arrigo Schieppati, Georgi Iskrov, László Gulácsi, Johann Matthias Graf von der Schulenburg, Panos Kanavos, Karine Chevreul1, Ulf Persson, Giovanni Fattore and BURQOL-RD Research Network, Social/Economic Costs and Quality of Life in Patients with Haemophilia in Europe, European Journal of Health Economics, Supplement, 2016 10.1007/s10198-016-0785-2 (accepted) IF (2014): 1. 774

Kuhlmann A, Schmidt T, Treskova M, López-Bastida J, Linertová R, Oliva-Moreno J, Serrano-Aguilar P, Posada-de-la-Paz M, Kanavos P, Taruscio D, Schieppati A,  Iskrov G, Péntek M, Delgado C, von der Schulenburg JM, Persson U, Chevreul K, Fattore G and the BURQOL-RD Research Network, Social/Economic Costs and Health-Related Quality of Life in Patients with Juvenile Idiopathic Arthritis in Europe, European Journal of Health Economics, Supplement, 2016 10.1007/s10198-016-0786-1 (accepted) IF (2014): 1.774

Márta Péntek, Lászlo Gulácsi, Valentin Brodszky, Petra Baji, Imre Boncz, Gábor Pogány, Julio López-Bastida, Renata Linertová, Juan Oliva-Moreno, Pedro Serrano-Aguilar, Manuel Posada-de-la-Paz, Domenica Taruscio, Georgi Iskrov, Arrigo Schieppati, Johann Matthias Graf von der Schulenburg, Panos Kanavos, Karine Chevreul, Ulf Persson, Giovanni Fattore and BURQOL-RD Research Network, Social/Economic Costs and Health-Related Quality of Life of Mucopolysaccharidosis Patients and Their Caregivers in Europe, European Journal of Health Economics, Supplement, 2016 10.1007/s10198-016-0787-0 (accepted) IF (2014): 1.774
http://link.springer.com/article/10.1007/s10198-016-0787-0?wt_mc=internal.event.1.SEM.ArticleAuthorOnlineFirst

Julio López-Bastida, Renata Linertová, Juan Oliva-Moreno, Manuel Posada-de-la-Paz, Pedro Serrano-Aguilar, Kanavos P, Taruscio D, Schieppati A, Iskrov G, Baji P, Delgado C, von der Schulenburg JM, Persson U, Chevreul K, Fattore G and the BURQOL-RD Research Network, Social/Economic Costs and Health-Related Qu ality of Life in Patients with Prader-Willi Syndrome in Europe, European Journal of Health Economics, Supplement, 2016, 10.1007/s10198-016-0788-z  (accepted) IF (2014): 1.774

Marianna Cavazza, Yllka Kodra, Patrizio Armeni, Marta De Santis, Julio López-Bastida, Renata Linertová, Juan Oliva-Moreno, Pedro Serrano-Aguilar, Manuel Posada-de-la-Paz, Domenica Taruscio, Arrigo Schieppati, Georgi Iskrov, Márta Péntek, Johann Matthias Graf von der Schulenburg, Panos Kanavos, Karine Chevreul, Ulf Persson, Giovanni Fattore and BURQOL-RD Research Network, Social/Economic Costs and Health-Related Quality of Life in Patients with Duchenne Muscular Dystrophy in Europe, European Journal of Health Economics, Supplement, 2016 10.1007/s10198-016-0782-5 (accepted) IF (2014): 1.774

Georgi Iskrov, Itziar Astigarraga, Rumen Stefanov, Julio López-Bastida, Renata Linertová, Juan Oliva-Moreno, Pedro Serrano-Aguilar, Manuel Posada-de-la-Paz, Arrigo Schieppati, Domenica Taruscio, Márta Péntek, Johann Matthias Graf von der Schulenburg, Panos Kanavos, Karine Chevreul, Ulf Persson, Giovanni Fattore and BURQOL-RD Research Network, Social/Economic Costs and Health-Related Quality of Life in Patients with Histiocytosis in Europe, European Journal of Health Economics, Supplement, 2016 10.1007/s10198-016-0790-5 (accepted) IF (2014): 1.774

Julio López-Bastida, Renata Linertová, Juan Oliva-Moreno, Pedro Serrano-Aguilar, Manuel Posada-de-la-Paz, Panos Kanavos, Domenica Taruscio, Arrigo Schieppati, Georgi Iskrov, Márta Péntek, Claudia Delgado, von der Johann Mathias Schulenburg, Ulf Persson, Karine Chevreul, Giovanni Fattore and the BURQOL-RD Research Network, Social/Economic Costs and Health-Related Quality of Life in Patients with Scleroderma in Europe, European Journal of Health Economics, Supplement, 2016 10.1007/s10198-016-0789-y (accepted) IF (2014): 1.774

Attila J Pulay, István Bitter, Szilvia Papp, László Gulácsi, Márta Péntek,  Valentin Brodszky, Noémi V.Hevér, Fanni Rencz,
Petra Baji, Exploring the relationship between quality of life (EQ-5D) and clinical measures in adult Attention Deficit Hyperactivity Disorder (ADHD), Applied Research on Quality of Life, 2016. accepted IF (2014): 0.818 DOI
10.1007/s11482-016-9467-6.

Péntek M, Herczegfalvi Ás, Molnár M, J, Szőnyi L,P, Kosztolányi Gy, Pfliegler Gy, Melegh B, Boncz I, Brodszky V, Baji P, Szegedi M, Pogány G, Gulácsi L, DUCHENNE-FÉLE IZOMDISZTRÓFIÁVAL ÉLÔ BETEGEK ÉS GONDOZÓIK BETEGSÉGTERHEI, Ideggyogy Sz 2016;69(5–6):183–193. IF (2014): 0.336

Petra Baji, László Gulácsi, Petra A. Golovics, Barbara D. Lovász, Márta Péntek, Valentin Brodszky, Fanni Rencz, Péter L. Lakatos, Perceived risks contra benefits of using biosimilar drugs in ulcerative colitis; discrete choice experiment among gastroenterologists, Value in Health Regional Issues, 2016.
http://www.valuehealthregionalissues.com/article/S2212-1099(16)30032-2/abstract#/article/S2212-1099(15)30012-1/fulltext

Fanni Rencz, László Gulácsi, Michael Drummond, Dominik Golicki, Valentina Prevolnik Rupel, Judit Simon, Elly A. Stolk, Valentin Brodszky, Petra Baji, Jakub Závada, Guenka Petrova, Alexandru Rotar, Márta Péntek, EQ-5D in Central and Eastern Europe: 2000–2015, Qual Life Res, 2016 Nov;25(11):2693-2710 (DOI 10.1007/s11136-016-1375-6) IF: 2,429

Alexandru M. Rotar, Alin Preda, Olga Löblová, Vanesa Benkovic, Szymon Zawodnik, Laszlo Gulacsi, Maciej Niewada, Imre Boncz, Guenka Petrova, Maria Dimitrova, Niek Klazinga, Rationalizing the introduction and use of pharmaceutical products: the role of managed entry agreements in Central and Eastern European countries, 2016, Health Policy (accepted) IF (2015): 2,194

A Bíró (2016): “Differences between subjective and predicted survival probabilities and their relation to preventive care use”, B. E. Journal of Economic Analysis and Policy. 16(2): 807-835. DOI: 10.1515/bejeap-2015-0154  IF (2014): 0.336
Public relations – 2016

 

2015.


 

Morandi M, Rencz F, Brodszky V, Moradi A, Balogh O, Gulácsi L. Health status and
quality of life in patients with psoriasis: An Iranian cross-sectional survey. Arch Iran Med.
2015; 18(3): 153-159. IF (2014): 0,936.

László Gulácsi, Valentin Brodszky, Petra Baji, HoUng Kim, Su Yeon Kim, Márta Péntek,
Biosimilars for the management of rheumatoid arthritis: economic considerations, Expert
Review of Clinical Immunology, 2015 Sep;11 Suppl 1:43-52. IF (2014): 2,180.

Valentin Brodszky, Fanni Rencz, Márta Péntek, Petra Baji, Péter L. Lakatos, László
Gulácsi. A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the
Czech Republic, Hungary, Poland, Romania and Slovakia. Expert Rev Pharmacoecon
Outcomes Res. 2015 Jul 10:1-7. IF (2014): 1,669.

Petra Baji, László Gulácsi, Barbara D. Lovász, Petra A. Golovics, Valentin Brodszky, Márta
Péntek, Fanni Rencz, Péter Lakatos. Treatment preferences of originator versus biosimilar
drugs in Crohn’s disease; discrete choice experiment among gastroenterologists. Scandinavian
Journal of Gastroenterology. 2015 June 10: 1-6. (doi: 10.3109/00365521.2015.1054422)
Early Online. IF (2014): 2,361.

Fanni Rencz, Márta Péntek, Martin Bortlik, Edyta Zagorowicz, Tibor Hlavaty, Andrzej
Śliwczyński, Mihai M Diculescu, Limas Kupcinskas, Krisztina B Gecse, László Gulácsi,
Peter L Lakatos, Biological therapy in inflammatory bowel diseases: access in Central and
Eastern Europe, World J Gastroenterol 2015 February 14; 21(6): 1728-1737. IF (2014): 2,369.

Fanni Rencz, Ágnes Kovács, Valentin Brodszky, László Gulácsi, Zalán Németh, Gábor
János Nagy, János Nagy, István Buzogány, Géza Böszörményi‑Nagy, Attila Majoros, Péter
Nyirády. Cost of illness of medically treated benign prostatic hyperplasia in Hungary. Int Urol
Nephrol; accepted for publication, doi 10.1007/s11255-015-1028-7. IF (2014): 1,519.

Fanni Rencz, Valentin Brodszky, Márta Péntek, Dániel Bereczki, László Gulácsi. Health
state utilities for migraine based on attack frequency: a time trade-off study.
NEUROLOGICAL SCIENCES 36:(2) pp. 197-202. (2015). IF (2014): 1,447.

Baji P, García-Goñi M, Gulácsi L, Mentzakis E, Paolucci F. Comparative analysis of
decision maker preferences for equity/efficiency attributes in reimbursement decisions in
three European countries. Eur J Health Econ. 2016 Jan;51(1):22-7. IF (2014): 1,774.

F. Rencz, L. Kemény, J.Z. Gajdácsi, W. Owczarek, P. Arenberger, G.S. Tiplica,7 A.
Stanimirovi, M. Niewada, G. Petrova, L.T. Marinov, M. Péntek, V. Brodszky, L. Gulácsi, Use
of biologics for psoriasis in Central and EasternEuropean countries, European Academy of
Dermatology and Venereology, 2015 Nov;29(11):2222-30. IF (2014): 2,826.

Fanni Rencz, László Gulácsi, Béla Tamási, Sarolta Kárpáti, Márta Péntek, Petra Baji,
Valentin Brodszky. Health related quality of life and its determinants in pemphigus: a
systematic review and meta-analysis. Br J Dermatol. 2015 Oct;173(4):1076-80. IF (2014):
4,275.

Fanni Rencz, Péter Holló, Sarolta Kárpáti, Márta Péntek, Éva Remenyik, Andrea Szegedi, Orsolya Balogh, Emese Herédi, K. Herszényi, Hajnalka Jókai, Valentin Brodszky, László Gulácsi. Moderate to severe psoriasis patients’ subjective future expectations regarding health-related quality of life and longevity. J Eur Acad Dermatol Venereol. 2015 Jul;29(7):1398-405. IF (2014): 2,826.

Fanni Rencz, Petra Baji, László Gulácsi, Sarolta Kárpáti, Márta Péntek, Adrienn Katalin
Poór, Valentin Brodszky, Is Dermatology Life Quality Index perfectly capable of
distinguishing health states of different quality of life? Quality of Life Research, közlésre
elfogadva IF (2014): 2,486
Baji P, Pavlova M, Gulácsi L, Groot W. Does the Implementation of Official User Charges
Help to Eradicate Informal Payments – Lessons to be Learnt from the Hungarian Experience.
Front Public Health. 2015 Jul 17;3:181.

P Baji, M Péntek, I Boncz, V Brodszky, O Loblova, N Brodszky, L Gulácsi The impact of
the recession on health care expenditure—How does the Czech Republic, Hungary, Poland
and Slovakia compare to other OECD countries? Society and Economy 2015. 37 (1), 73-88.

Hevér NV, Péntek M, Balló A, Gulácsi L, Baji P, Brodszky V, Damásdi M, Bognár Z,
Tóth G, Buzogány I, Szántó Á. Health related quality of life in patients with bladder cancer: a
cross-sectional survey and validation study of the Hungarian version of the Bladder Cancer
Index. Pathol Oncol Res. 2015 Jul;21(3):619-27. IF: 1,855

 

2014


 

Péntek M, Brodszky V, Gulácsi L, Hajdú O, van Exel J, Brouwer W, Gulácsi L.
Subjective expectations regarding length and health-related quality of life in Hungary:
results from an empirical investigation. Health Expect. 2014 Oct;17(5):696-709. doi:
10.1111/j.1369-7625.2012.00797.x. Epub 2012 Jun 28. IF (2013): 2,852

Tamás G, Gulácsi L, Bereczki D, Baji P, Takáts A, Brodszky V, Péntek M, Quality of
Life and Costs in Parkinson’s Disease: A Cross Sectional Study in Hungary. PLoS
ONE 2014 Sep 17;9(9):e107704. IF (2013): 3,534

Rencz F, Holló P, Kárpáti S, Péntek M, Remenyik É, Szegedi A, Balogh O, Herédi E,
Herszény K, Jókai H, Brodszky V, Gulácsi L. Moderate to severe psoriasis patients’
subjective future expectations regarding health-related quality of life and longevity,
Journal of the European Academy of Dermatology and Venereology, DOI:
10.1111/jdv.12884. 2014. IF (2013): 3,105

Noémi V. Hevér, Márta Péntek, András Balló, Petra Baji, Valentin Brodszky, Miklós
Damásdi, Zita Bognár, György Tóth, István Buzogány, Árpád Szántó. Translation and
validation of the Hungarian language version of Bladder Cancer Index questionnaire,
2014. Dec 1. [Epub ahead of print], doi 10.1007/s12253-014-9866-7 Pathology and
Oncology Research IF (2013): 1,806.

Baji, P., Péntek, M., Czirják, L., Szekanecz, Z., Nagy, G., Gulácsi, L., Brodszky, V.
Efficacy and safety of infliximab-biosimilar compared to other biological drugs in
rheumatoid arthritis: a mixed treatment comparison. Eur J Health Econ. 2014, 15
Suppl 1, 53-64. IF (2013): 1,913

Baji, P., Péntek, M., Szanto, S., Geher, P., Gulacsi, L., Balogh, O., Brodszky, V.
Comparative efficacy and safety of biosimilar infliximab and other biological
treatments in ankylosing spondylitis: systematic literature review and meta-analysis.
Eur J Health Econ. 2014, 15 Suppl 1, 45-52. IF (2013): 1,913

Péntek, M., Poór, G., Wiland, P., Olejarova, M., Brzosko, M., Codreanu, C.,
Brodszky, N., Gulácsi, L. Biological therapy in inflammatory rheumatic diseases:
issues in Central and Eastern European countries. Eur J Health Econ. 2014, 15 Suppl
1, S35-43. IF (2013): 1,913

Péntek, M., Rojkovich, B., Czirjak, L., Geher, P., Keszthelyi, P., Kovacs, A., Kovacs,
L., Szabo, Z., Szekanecz, Z., Tamasi, L., Toth, A. E., Ujfalussy, I., Hever, N. V.,
Strbak, B., Baji, P., Brodszky, V., Gulácsi, L. Acceptability of less than perfect health
states in rheumatoid arthritis: the patients’ perspective. Eur J Health Econ. 2014, 15
Suppl 1, S73-82. IF (2013): 1,913

Péntek M, Gulácsi L, Rojkovich B, Brodszky V, van Exel J, Brouwer WBF.
Subjective health expectations at biological therapy initiation: a survey of rheumatoid
arthritis patients and rheumatologists. Eur J Health Econ 2014, 15 (Suppl 1):S83–S92,
DOI 10.1007/s10198-014-0597-1. IF (2013): 1,913

Brodszky, V., Baji, P., Balogh, O., Péntek, M. Budget impact analysis of biosimilar
infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and
Eastern European countries. Eur J Health Econ. 2014, 15 Suppl 1, S65-71. IF (2013):
1,913

Gulácsi, L., Rencz, F., Péntek, M., Brodszky, V., Lopert, R., Hever, N. V., Baji, P.
Transferability of results of cost utility analyses for biologicals in inflammatory
conditions for Central and Eastern European countries. Eur J Health Econ. 2014, 15
Suppl 1, S27-34. IF (2013): 1,913

Gulácsi, L., Rotar, A. M., Niewada, M., Loblova, O., Rencz, F., Petrova, G., Boncz, I.,
Klazinga, N. S. Health technology assessment in Poland, the Czech Republic,
Hungary, Romania and Bulgaria. Eur J Health Econ. 2014, 15 Suppl 1, 13-25. IF
(2013): 1,913

Mandel MD, Bálint A, Lovász BD, Gulácsi L, Strbák B, Golovics PA, Farkas K, Kürti
Z, Szilágyi BK, Mohás A, Molnár T, Lakatos PL. Work disability and productivity
loss in patients with inflammatory bowel diseases in Hungary in the era of biologics.
Eur J Health Econ. 2014, 15 Suppl 1:S121-8. doi: 10.1007/s10198-014-0603-7. Epub
2014 May 16. Erratum in: Eur J Health Econ. 2014 May;15 Suppl 1;S129. Michael,
Mandel D [corrected to Mandel, Michael D]. IF (2013): 1,913

Rencz, F., Brodszky, V., Péntek, M., Bereczki, D., Gulácsi, L. Health state utilities for
migraine based on attack frequency: a time trade-off study. Neurol Sci. 2014,
10.1007/s10072-014-1920-4. IF (2013): 1,495

S. Evans-Lacko, E. Courtin, A. Fiorillo, M. Knapp, M. Luciano, A.-L. Park,M. Brunn,
S. Byford, K. Chevreul, A.K. Forsman, L. Gulacsi, J.M. Haro, B. Kennelly, S.
Knappe, T. Lai, A. Lasalvia, M. Miret, C. O’Sullivan,14, C. Obradors-Tarrago´, N.
Ru¨ sch , N. Sartorius, V. Sˇvab v, J. van Weeghel,C. Van Audenhove , K. Wahlbeck ,
A. Zlati ROAMER Consortium, D. McDaid ,G. Thornicroft. The state of the art in
European research on reducing social exclusion and stigma related to mental health: A
systematic mapping of the literature. Eur Psychiatry. 2014, 29(6):381-9. IF (2013):
3,210

Gulácsi, L., Pentek, M. HTA in Central and Eastern European countries; the 2001: A
Space Odyssey and efficiency gain. Eur J Health Econ. 2014, 15(7):675-80. IF
(2013): 1,913

Gulácsi, L. Biological and biosimilar therapies in inflammatory conditions: challenges
for the Central and Eastern European countries. Eur J Health Econ. 2014, 15 Suppl 1,
1-4. IF (2013): 1,913

Hatvani Z, Brodszky V, Mazán M, Pintér D, Hársing J, Tóth V, Somlai B, Kárpáti S.
Genotype analysis in Hungarian patients with multiple primary melanoma. Exp
Dermatol. 2014 May;23(5):361-4. IF (2013):4,115

Balogh O, Brodszky V, Gulácsi L, Herédi M, Herszényi K, Jókai H, Kárpáti , Baji P,
Remenyik E, Szegedi A, Holló P. Cost-of-illness in patients with moderate to severe
psoriasis: a cross-sectional survey in Hungarian dermatological centres, Eur J Health
Econ, 2014;15 Suppl 1:S101-9. IF (2013): 1,913

Herédi E, Rencz F, Balogh O, Gulácsi L, Herszényi K, Holló P, Jókai H, Kárpáti S,
Péntek M, Remenyik É, Szegedi A, Brodszky V. Exploring the relationship between
EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in
psoriasis from Hungary, Eur J Health Econ, 2014 15 Suppl 1:S111-9. IF (2013): 1,913

Baji P, Pavlova M, Gulácsi L, Farkas M, Groot W. The link between past informal
payments and willingness of the Hungarian population to pay formal fees for health
care services: results from a contingent valuation study. Eur J Health Econ.
2014;15(8):853-67. doi: 10.1007/s10198-013-0531-y. Epub 2013 Aug 30. IF (2013):
1,913

Fanni Rencz, Márta Péntek, Martin Bortlik, Edyta Zagorowicz, Tibor Hlavaty,
Andrzej Liwczyński, Mihai M Diculescu, Limas Kupcinskas, Krisztina B Gecse,
László Gulácsi, Peter L Lakatos. Biological therapy in inflammatory bowel diseases:
Access in Central and Eastern Europe. World Journal of Gastroenterology, 2014.
IF (2013): 2,433

Putrik P, Ramiro S, Kvien TK, Sokka T, Uhlig T, Boonen A. Egyéb szerzőség: Collaku L, Harutyunyan R, Pentek M. (kollaborációs közrem.); Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country’s wealth? ANNALS OF THE RHEUMATIC DISEASES 73:(11) pp. 2010-2021. (2014)

Hevér NV, Péntek M, Balló A, Gulácsi L, Baji P, Brodszky V, Damásdi M, Bognár
Z, Tóth G, Buzogány I, Szántó A. Health Related Quality of Life in Patients with
Bladder Cancer: A Cross-Sectional Survey and Validation Study of the Hungarian
Version of the Bladder Cancer Index. Pathol Oncol Res. 2014 Dec 1. [Epub ahead of
print] PubMed PMID: 25434791.

 

2013.


Baji P, Pavlova M, Gulácsi L, Farkas M, Groot W. The link between past informal
payments and willingness of the Hungarian population to pay formal fees for health
care services: results from a contingent valuation study. EUROPEAN JOURNAL OF
HEALTH ECONOMICS. 2013 Aug 30. doi: 10.1007/s10198-013-0531-y
(Forthcoming) IF (2012): 2,01

Baji P, Pavlova M, Gulacsi L, Groot W. Exploring consumers’ attitudes towards
informal patient payments using the combined method of cluster and multinomial
regression analysis – the case of Hungary, BMC HEALTH SERVICES
RESEARCH 13:(1) p. 62. (2013) IF (2012):1,773

Vártokné Hevér N, Balogh O. German approach to cost-effectiveness analysis in
health care, SOCIETY AND ECONOMY, 33(4): 1-22. (2013)

 

2012.


Simoens S, Dunselman G, Dirksen C, Hummelshoj L, Bokor A, Brandes I, Brodszky V, Canis M, Colombo GL, Deleire T, Falcone T, Graham B, Halis G, Horne A, Kanj O, Kjer JJ, Kristensen J, Lebovic D, Mueller M, Vigano P, Wullschleger M, D’Hooghe T. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum Reprod. 2012 May;27(5):1292-9. IF: 4,670

Baji P, Pavlova M, Gulácsi L, Groot W. Changes in equity in out-of-pocket
payments during the period of health care reforms: evidence from Hungary. Int J
Equity Health. 2012 Jul 24;11:36. doi: 10.1186/1475-9276-11-36. PubMed PMID:
22828250; PubMed Central PMCID: PMC3439316.

Baji P, Pavlova M, Gulácsi L, Zsófia HC, Groot W. Informal payments for
healthcare services and short-term effects of the introduction of visit fee on
these payments in Hungary. Int J Health Plann Manage. 2012 Jan-Mar;27(1):63-79.
doi: 10.1002/hpm.1106. Epub 2011 Oct 18. PubMed PMID: 22009836.

Gulácsi L, Orlewska E, Péntek M. Health economics and health technology
assessment in Central and Eastern Europe: a dose of reality. Eur J Health Econ.
2012 Oct;13(5):525-31. doi: 10.1007/s10198-012-0411-x. PubMed PMID: 22729215.

Hegyi M, Gulácsi A, Cságoly E, Csordás K, Eipel OT, Erdélyi DJ, Müller J,
Nemes K, Lautner-Csorba O, Kovács GT. Clinical relations of methotrexate
pharmacokinetics in the treatment for pediatric osteosarcoma. J Cancer Res Clin
Oncol. 2012 Oct;138(10):1697-702. Epub 2012 Jun 1. PubMed PMID: 22652833.

 

2011.


Sevcic K, Orban I, Brodszky V, Bazso A, Balogh Z, Poor G, Kiss E: Experiences with Tumour Necrosis Factor Alpha Inhibitors in Patients with Juvenile Idiopathic Arthritis. Hungarian Data from the National Institute of Rheumatology and Physiotherapy Registry. Rheumatology (Oxford), 2011;50(7):1337-40. IF: 4,171

Baji P, Pavlova M, Gulácsi L, Groot W. User fees for public health care
services in Hungary: expectations, experience, and acceptability from the
perspectives of different stakeholders. Health Policy. 2011 Oct;102(2-3):255-62.
doi: 10.1016/j.healthpol.2011.03.001. Epub 2011 May 4. PubMed PMID: 21536338

 

 

2010.


Brodszky V, Orlewska E, Péntek M, Kárpáti K, Skoupá J, Gulácsi L: Challenges in economic evaluation of new drugs: experience with rituximab in Hungary Med Sci Monit 2010;16(1):SR1-5 IF: 1,699

Brodszky V, Péntek M, Bálint PV, Géher P, Hajdú O, Hodinka L, Horváth G, Koó É, Polgár A, Seszták M, Szántó S, Ujfalussy I, Gulácsi L: Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and the utility (EQ-5D) measures in psoriatic arthritis; results from a cross-sectional survey Scand J Rheum 2010;39(4):303-309 IF: 2,594

Boncz I, Brodszky V, Péntek M, Agoston I, Nagy Z, Kárpáti K, Kriszbacher I, Fuszek P, Gulácsi L: The disease burden of colorectal cancer in Hungary. Eur J Health Econ 2010;10(Suppl 1):S35-40 IF: 1, 755

Minier T, Péntek M, Brodszky V, Ecseki A, Kárpáti K, Polgár A, Czirják L, Gulácsi L: Cost-of-illness of patients with systemic sclerosis in a tertiary care centre. Rheumatology, 2010;49(10): 1920-1928 IF: 4,171

Érsek K, Kovács T, Wimo A, Kárpáti K, Brodszky V, Péntek M, Jönsson L, Gustavsson A, McDaid D, Kenigsberg PA, Valtonen H, Gulácsi L: Costs of dementia in Hungary. J Nutr Health Aging, 2010;14(8):633-9. IF: 2,484

Koncz T, Pentek M, Brodszky V, Érsek K, Orlevska E, Gulacsi L: Adherence to biologic DMARD therapies in Rheumatoid Arthritis. Expert Opin Biol Ther, 2010;10(9),1367-1378 IF: 3,279

Gulácsi Z, Kampf A, Vollhardt D. Route to ferromagnetism in organic polymers.
Phys Rev Lett. 2010 Dec 31;105(26):266403. Epub 2010 Dec 22. PubMed PMID:
21231689.

 

 

2009.


Brodszky V, Balint P, Geher P, Hodinka L, Horvath G, Koo E, Pentek M, Polgar A, Sesztak M, Szanto S, Ujfalussy I, Gulacsi L: Disease Burden of Psoriatic Arthritis Compared to Rheumatoid Arthritis, Hungarian Experiment. Rheum Int 2009;30(2):199-205 IF: 1,493

Gulácsi L, Brodszky V, Péntek M, Kárpáti K, Varga S, Vas G, Boncz I: History of health technology assessment (HTA) in Hungary, International Journal of Technology Assessment in Health Care, 2009;25 Suppl 1:120-126 IF: 1,794

Sebestyen A, Boncz I, Molnar A, Korosi L, Kovi R, Kriszbacher I, Olah A, Pentek M, Sandor J. RELATIONSHIP BETWEEN SURGICAL INTERVENTION TYPE AND 30 DAYS MORTALITY OF ELDERLY FEMORAL NECK FRACTURE IN THE PRSENCE OF DIFFERENT CO-MORBIDITIES. VALUE IN HEALTH 12:(3) p. A66. (2009)

Makai P, Klazinga N, Wagner C, Boncz I, Gulacsi L. Quality management and
patient safety: survey results from 102 Hungarian hospitals. Health Policy. 2009
May;90(2-3):175-80. doi: 10.1016/j.healthpol.2008.09.009. Epub 2008 Nov 11.
PubMed PMID: 19004518.

 

2008.


Pentek M, Horvath C, Boncz I, Falusi Z, Toth E, Sebestyen A, Majer I, Brodszky V, Gulacsi L: Epidemiology of osteoporosis related fractures in Hungary from the nationwide health insurance database, 1999-2003. Osteoporos Int. 2008;19:243-9 IF: 4,290

Brodszky V, Péntek M, Gulácsi L: Efficacy of adalimumab, etanercept and infliximab in psoriatic arthritis based on ACR50 response after 24 weeks treatment. Scand J Rheumatol 2008;37:399-400 IF: 2,345

Brodszky V, Péntek M, Kárpáti K, Orlewska E, Gulácsi L, Analiza ekonomiczna rituksymabu w leczeniu reumatoidalnego zapalenia stawów na Węgrzech (Economic evaluation of rituximab in the treatment of rheumatoid arthritis in Hungary), Farmakoekonomika (Varsó), 2008;12:10-16.

Brodszky V, Pentek M, Gulacsi L. Efficacy of adalimumab, etanercept, and
infliximab in psoriatic arthritis based on ACR50 response after 24 weeks of
treatment. Scand J Rheumatol. 2008 Sep-Oct;37(5):399-400. doi:
10.1080/03009740802004966. PubMed PMID: 18821278.